

HIV Capsid as a Drug Target

Prelims: Current events of national and international importance | Science & Technology

Why in News?

A recent study has confirmed that the HIV capsid remains an effective drug target even when resistance develops, reaffirming the potential of drug lenacapavir and opens door for a new generation of HIV drugs.


- **HIV** - HIV (Human Immunodeficiency Virus) is **a type of RNA virus.**

Viruses contain either DNA or RNA as genetic material, where DNA viruses are more stable and replicate in the nucleus, while RNA viruses mutate rapidly and evolve quickly.

- HIV attacks the body's immune system. Without treatment, it can lead to AIDS (acquired immunodeficiency syndrome).
- Once people get HIV, they have it for life. But proper medical care can control the virus.

A mutation is a permanent change in the genetic material of a cell or microorganism.

- **HIV Mutation** - HIV mutates rapidly while converting its RNA into DNA, creating many variants.
- Some viral parts are vital for survival and cannot change much, such as the HIV capsid protein.
- **HIV Capsid** - The capsid is a **protective protein shell surrounding the viral RNA.**



Key Findings

- **First HIV Drug** - In 1987, the first HIV drug, *zidovudine*, targeted the enzyme reverse transcriptase.
 - **Resistance** - The drug slowed the virus, but the virus soon became resistant.
- **Target "Must-Keep" Regions** - Researchers focus on essential viral components that cannot mutate without stopping the virus from functioning, effectively closing the window for resistance.
- **Combination Therapy** - This led to the development of combination antiretroviral therapy targeting multiple viral proteins such as reverse transcriptase, protease, and integrase.
- **1999 study** - Found that the capsid forms a unique 3D shape necessary for the virus to survive.
- **Mutation Defect** - Drug-resistant HIV viruses had mutations in specific capsid positions in order to escape the drug, which damaged their own capsid.
- **Efficacy** - Most changes in the capsid protein stop the virus from infecting cells.
- **Lenacapavir** - Initially faced poor water solubility, which is usually a problem for medicines to circulate effectively in the body.
- **Advantage** - This low solubility later became an advantage, allowing it to form a slow-release reservoir under the skin and work for six months with a single injection.

Lenacapavir is the world's first capsid-based HIV inhibitor approved in 2025 by the U.S. Food and Drug Administration.

- **Lenacapavir Effect** - Patients treated with lenacapavir showed small mutations in the virus's capsid protein that diminished the drug's effect.
- **Monotherapy Resistance** - Resistance mainly developed when lenacapavir was used alone. When used with other active HIV drugs (combination therapy), the virus remained well controlled.
- **High Efficacy** - Showed 100% effectiveness in preventing HIV infection in high-risk individuals.
- **Result** - Lenacapavir in combination therapy made the virus weaker, and the resistant viruses ***multiplied at only 20-30% of their normal rate.***
- But it is *not a cure, and is considered close to an HIV vaccine* in preventive potential.

Reference

[TH | HIV capsid](#)

